$ARMP
Armata Pharmaceuticals, Inc.

2019 Q1 Form 10-Q Financial Statement

#000114420419023904 Filed on May 06, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2018 Q1
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.380M $1.475M $1.590M
YoY Change -13.21% 13.46% -16.32%
% of Gross Profit
Research & Development $1.494M $1.375M $1.464M
YoY Change 2.05% 26.15% -1.74%
% of Gross Profit
Depreciation & Amortization $100.0K $90.00K $89.00K
YoY Change 12.36% 0.0% -11.0%
% of Gross Profit
Operating Expenses $3.606M $2.850M $3.055M
YoY Change 18.04% 19.25% -9.88%
Operating Profit -$3.606M -$3.055M
YoY Change 18.04%
Interest Expense -$298.0K $132.0K -$80.00K
YoY Change 272.5% 1220.0% -172.73%
% of Operating Profit
Other Income/Expense, Net -$11.00K $0.00 -$79.00K
YoY Change -86.08%
Pretax Income -$3.739M -$4.648M -$3.130M
YoY Change 19.46% 97.79% -3.69%
Income Tax -$328.0K
% Of Pretax Income
Net Earnings -$3.617M -$4.320M -$3.134M
YoY Change 15.41% 83.83% -3.57%
Net Earnings / Revenue
Basic Earnings Per Share -$0.11 -$0.24
Diluted Earnings Per Share -$0.11 -$2.038M -$0.24
COMMON SHARES
Basic Shares Outstanding 32.39M 32.29M 13.30M
Diluted Shares Outstanding 32.39M 13.30M

Balance Sheet

Concept 2019 Q1 2018 Q4 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.535M $8.157M $8.210M
YoY Change -32.58% 59.01% 273.18%
Cash & Equivalents $5.535M $8.157M $8.206M
Short-Term Investments
Other Short-Term Assets $407.0K $251.0K $540.0K
YoY Change -24.63% 0.4% 58.82%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.942M $8.408M $8.740M
YoY Change -32.01% 56.14% 241.41%
LONG-TERM ASSETS
Property, Plant & Equipment $420.0K $503.0K $730.0K
YoY Change -42.47% -38.36% -25.51%
Goodwill
YoY Change
Intangibles $2.731M $2.731M
YoY Change -41.41%
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $3.675M $3.479M $5.660M
YoY Change -35.07% -39.53% -51.79%
TOTAL ASSETS
Total Short-Term Assets $5.942M $8.408M $8.740M
Total Long-Term Assets $3.675M $3.479M $5.660M
Total Assets $9.617M $11.89M $14.40M
YoY Change -33.22% 6.72% 0.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.757M $729.0K $810.0K
YoY Change 116.91% 26.12% -27.03%
Accrued Expenses $1.834M $1.805M $970.0K
YoY Change 89.07% 29.86% 10.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.591M $2.572M $1.780M
YoY Change 101.74% 30.69% -38.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $246.0K $22.00K $190.0K
YoY Change 29.47% -92.41% -91.85%
Total Long-Term Liabilities $246.0K $22.00K $190.0K
YoY Change 29.47% -92.41% -91.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.591M $2.572M $1.780M
Total Long-Term Liabilities $246.0K $22.00K $190.0K
Total Liabilities $4.656M $3.413M $3.110M
YoY Change 49.71% 0.18% -59.35%
SHAREHOLDERS EQUITY
Retained Earnings -$406.3M
YoY Change 3.07%
Common Stock $323.0K
YoY Change 240.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.961M $8.474M $11.29M
YoY Change
Total Liabilities & Shareholders Equity $9.617M $11.89M $14.40M
YoY Change -33.22% 6.72% 0.7%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2018 Q1
OPERATING ACTIVITIES
Net Income -$3.617M -$4.320M -$3.134M
YoY Change 15.41% 83.83% -3.57%
Depreciation, Depletion And Amortization $100.0K $90.00K $89.00K
YoY Change 12.36% 0.0% -11.0%
Cash From Operating Activities -$2.620M -$2.428M -$3.536M
YoY Change -25.9% 2.45% 7.15%
INVESTING ACTIVITIES
Capital Expenditures $7.000K -$3.000K $0.00
YoY Change -85.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$7.000K -$3.000K $0.00
YoY Change -85.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.000K 6.089M 6.610M
YoY Change -99.92% -2999.52% -3247.62%
NET CHANGE
Cash From Operating Activities -2.620M -2.428M -3.536M
Cash From Investing Activities -7.000K -3.000K 0.000
Cash From Financing Activities 5.000K 6.089M 6.610M
Net Change In Cash -2.622M 3.658M 3.074M
YoY Change -185.3% -240.69% -187.33%
FREE CASH FLOW
Cash From Operating Activities -$2.620M -$2.428M -$3.536M
Capital Expenditures $7.000K -$3.000K $0.00
Free Cash Flow -$2.627M -$2.425M -$3.536M
YoY Change -25.71% 3.19% 7.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 aphb Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
223000
CY2018Q1 aphb Proceeds From Equity Offerings Gross
ProceedsFromEquityOfferingsGross
4000000
CY2018Q1 aphb Proceeds From Equity Offerings Gross
ProceedsFromEquityOfferingsGross
3000000
CY2018Q1 aphb Proceeds From Sale Of Common Stock Net Of Offering Costs
ProceedsFromSaleOfCommonStockNetOfOfferingCosts
6409000
CY2019Q1 aphb Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Ii
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi
P7Y6M15D
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5132000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8206000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3074000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2622000
CY2019Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
26480505
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000921114
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33469008
CY2019Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
AmpliPhi Biosciences Corp
CY2019Q1 dei Trading Symbol
TradingSymbol
APHB
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1220000
CY2019Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1757000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
122000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
99000
CY2018Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8000
CY2019Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9420075
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27344397
CY2019Q1 us-gaap Assets
Assets
9617000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
8408000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
5942000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8157000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5535000
CY2019Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
29767968
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32294008
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32774690
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32294008
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32774690
CY2019Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
819000
CY2018Q1 us-gaap Depreciation
Depreciation
89000
CY2019Q1 us-gaap Depreciation
Depreciation
100000
CY2018Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
22000
CY2019Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
33000
CY2018Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-79000
CY2019Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-11000
CY2018Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
22000
CY2019Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
33000
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1352000
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1834000
CY2019Q1 us-gaap Employee Stock Ownership Plan Esop Number Of Committed To Be Released Shares
EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares
76472
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
245000
CY2019Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
238000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1591000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2112000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-61000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
453000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-355000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
482000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
284000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
156000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2731000
CY2019Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2731000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3591000
CY2019Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
11000
CY2019Q1 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
213000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6610000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3536000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2620000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3134000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3617000
CY2018Q1 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-3134000
CY2019Q1 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-3617000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
3055000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
3606000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3055000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3606000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
286000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-79000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
251000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
407000
CY2018Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3000
CY2018Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3400000
CY2018Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2800000
CY2018Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
198000
CY2019Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
503000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
420000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1464000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1494000
CY2018Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
4000000
CY2018Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2743640
CY2018Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.00
CY2018Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.10
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
863892
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.79
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1150065
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
863892
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.08
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.79
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11D
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
122000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
99000
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
502392
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.11
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M29D
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
286173
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M15D
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.95
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Use of Estimates</font> </p> <p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font> </p> <p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#x2019;s estimates.</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13298159
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32390144
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13298159
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32390144
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13298159
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32390144

Files In Submission

Name View Source Status
0001144204-19-023904-index-headers.html Edgar Link pending
0001144204-19-023904-index.html Edgar Link pending
0001144204-19-023904.txt Edgar Link pending
0001144204-19-023904-xbrl.zip Edgar Link pending
aphb-20190331.xml Edgar Link completed
aphb-20190331.xsd Edgar Link pending
aphb-20190331_cal.xml Edgar Link unprocessable
aphb-20190331_def.xml Edgar Link unprocessable
aphb-20190331_lab.xml Edgar Link unprocessable
aphb-20190331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv520676_10q.htm Edgar Link pending
tv520676_ex31-1.htm Edgar Link pending
tv520676_ex31-2.htm Edgar Link pending
tv520676_ex32-1.htm Edgar Link pending
tv520676_ex32-2.htm Edgar Link pending